AKT1 and melanoma: We and others, for example, identified the rapid phosphorylation of the ErbB3 receptor and the activation of the downstream AKT pathway as a key event responsible for the development of resistance to targeted therapies in melanoma through the activation of a feedback autocrine survival loop involving increased production the ErbB3 ligand neuregulin1 (NRG1) [30, 31].